Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
MATHS: Assessment of Health-status of Patients With COPD on MAintenance THerapy With Spiriva® HH Measured by CAT Test
Sponsor: Boehringer Ingelheim
Listed as NCT01644734, this PHASE4 trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Andrychów, Poland , Bialystok, Poland , Bielsko-Biala, Poland , Biskupiec, Poland , Bochnia, Poland , Brzesko, Poland , Brzeziny, Poland , Brzozów, Poland , Bydgoszcz, Poland , Chełm, Poland and 135 more locations